Literature DB >> 21172872

Altered peptide ligands make their entry.

Emil R Unanue1.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21172872     DOI: 10.4049/jimmunol.1090118

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  6 in total

1.  PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.

Authors:  Brian T Rekoske; Heath A Smith; Brian M Olson; Brett B Maricque; Douglas G McNeel
Journal:  Cancer Immunol Res       Date:  2015-06-03       Impact factor: 11.151

Review 2.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

3.  DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

Authors:  Heath A Smith; Brian T Rekoske; Douglas G McNeel
Journal:  Vaccine       Date:  2014-01-31       Impact factor: 3.641

4.  Backbone Modifications of HLA-A2-Restricted Antigens Induce Diverse Binding and T Cell Activation Outcomes.

Authors:  Ruslan Gibadullin; Caleb J Randall; John Sidney; Alessandro Sette; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2021-04-21       Impact factor: 15.419

5.  Vaccination with Altered Peptide Ligands of a Plasmodium berghei Circumsporozoite Protein CD8 T-Cell Epitope: A Model to Generate T Cells Resistant to Immune Interference by Polymorphic Epitopes.

Authors:  Gabriela Minigo; Katie L Flanagan; Robyn M Slattery; Magdalena Plebanski
Journal:  Front Immunol       Date:  2017-02-14       Impact factor: 7.561

Review 6.  Diversity-oriented approaches for interrogating T-cell receptor repertoire, ligand recognition, and function.

Authors:  Michael E Birnbaum; Shen Dong; K Christopher Garcia
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.